Collegium PharmaceuticalCOLL
About: Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Employees: 357
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
235% more call options, than puts
Call options by funds: $617K | Put options by funds: $184K
23% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 26
1.4% more ownership
Funds ownership: 115.16% [Q4 2024] → 116.56% (+1.4%) [Q1 2025]
3% more capital invested
Capital invested by funds: $1.06B [Q4 2024] → $1.1B (+$30.9M) [Q1 2025]
0% more funds holding
Funds holding: 238 [Q4 2024] → 239 (+1) [Q1 2025]
22% less repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 97
100% less funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 0 (-1) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Piper Sandler David Amsellem | 27%upside $37 | Neutral Reiterated | 9 May 2025 |
Needham Serge Belanger | 58%upside $46 | Buy Reiterated | 9 Apr 2025 |
HC Wainwright & Co. Oren Livnat | 71%upside $50 | Buy Reiterated | 24 Mar 2025 |
Financial journalist opinion









